Cargando…
Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
As members of the immune checkpoint family, PD-1 and its ligand PD-L1 play critical roles in maintaining the balance between autoimmunity and tolerance. The interaction of PD-1/PD-L1 is also involved in tumor evasion inside the tumor microenvironment, caused by reduced T cell activation, proliferati...
Autores principales: | Ding, Peng, Ma, Zhiqiang, Fan, Yizeng, Feng, Yingtong, Shao, Changjian, Pan, Minghong, Zhang, Yimeng, Huang, Di, Han, Jing, Hu, Yi, Yan, Xiaolong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chongqing Medical University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308071/ https://www.ncbi.nlm.nih.gov/pubmed/37396527 http://dx.doi.org/10.1016/j.gendis.2022.01.002 |
Ejemplares similares
-
Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy
por: Ding, Peng, et al.
Publicado: (2022) -
Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022) -
ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy
por: Xiao, Xiangling, et al.
Publicado: (2023) -
Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy
por: Jiang, Yao, et al.
Publicado: (2023) -
The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
por: Hou, Bo, et al.
Publicado: (2023)